USFDA18 Dec 2025, 08:32 am
Sun Pharma's Baska Facility Receives OAI Classification from US FDA
AI Summary
Sun Pharmaceutical Industries Ltd. has announced that the US FDA has determined the inspection classification status of its Baska facility as Official Action Indicated (OAI) following an inspection conducted from 8 September 2025 to 19 September 2025. The company will continue to manufacture and supply approved products from the facility to the US market and work with the regulator to achieve fully compliant status.
Key Highlights
- US FDA inspects Sun Pharma's Baska facility from 8 September 2025 to 19 September 2025
- Baska facility receives OAI classification from US FDA
- Sun Pharma to continue manufacturing and supplying approved products from the facility to the US market
- Company to work with the regulator to achieve fully compliant status